Anaptysbio (ANAB) EBITDA Margin Growth (5y) (2021 - 2026)
Anaptysbio (ANAB) EBITDA Margin Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,808.00 |
| Dec 31, 2025 | 3,363.00 |
| Mar 31, 2025 | 10,590.00 |
| Dec 31, 2024 | 70,325.00 |
| Jun 30, 2024 | 16,562.00 |
| Sep 30, 2023 | -79,945.00 |
| Dec 31, 2022 | -28,109.00 |
| Jun 30, 2022 | -220,094.00 |
| Dec 31, 2021 | -276,440.00 |
| Sep 30, 2021 | 7,368.00 |
| Jun 30, 2021 | -6,174.00 |
| Mar 31, 2021 | -15,514.00 |